Abstract
Thirty-three patients with vaginal candidosis were treated with natamycin vaginal tablets for 10 days and their partners were treated double-blind with natamycin cream/placebo cream. Follow-up examinations were carried out one week after the treatment was discontinued and again about one month later. The cure rate in patients having actively treated partners was 94%, not differing significantly from the cure rate of 88% in patients whose partners had been treated with placebo. One month after the treatment there was a high recurrence/re-infection rate, about 30% in both groups. Thus, treating the partners of patients with vaginal candidosis has no influence upon the therapeutic outcome or recurrence rate. The recurrence is presumably due to re-infection from the patient herself.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
